Jove
Visualize
Contact Us

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

544
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
544
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

143
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
143
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

145
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
145
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

143
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
143
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

129
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
129
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

166
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polymorphic Loci of Xenobiotic Biotransformation Genes in Accumulated Mercury Pollution Liquidators and in Workers with Chronic Mercury Vapors Exposure.

Bulletin of experimental biology and medicine·2024
Same author

Role of cytochrome P450-dependent monooxygenases and polymorphic variants of GSTT1 and GSTM1 genes in the formation of brain lesions in individuals chronically exposed to mercury.

Bulletin of experimental biology and medicine·2013
Same author

Dependence of blood levels of HSP70 and HSP90 on genotypes of HSP70, GSTT1, and GSTM1 gene polymorphism in individuals chronically exposed to mercury.

Bulletin of experimental biology and medicine·2013
Same author

Effects of CYP1A2 gene polymorphisms on antipyrine CYP1A2-dependent metabolism.

Bulletin of experimental biology and medicine·2012
Same author

Polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls in the serum of firefighters who participated in extinguishing the 1992 fire at a cable manufacturing plant in Irkutsk oblast.

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections·2010
Same author

Peroxidation processes in rats during the delayed period after chronic administration of dihydroquercetin.

Bulletin of experimental biology and medicine·2009
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Dec 26, 2025

An Anaerobic Biosensor Assay for the Detection of Mercury and Cadmium
09:33

An Anaerobic Biosensor Assay for the Detection of Mercury and Cadmium

Published on: December 17, 2018

10.7K

CYP3A Polymorphism and Chronic Mercury Intoxication.

Yu I Chernyak1, A P Merinova2

  • 1East-Siberian Institute of Medical and Ecological Research, Angarsk, Russia. yuri_chernyak@hotmail.com.

Bulletin of Experimental Biology and Medicine
|March 9, 2020
PubMed
Summary

Genetic variations in CYP3A genes may influence chronic mercury intoxication. A study found trends suggesting increased rare alleles in CYP3A5 and CYP3A7 in exposed individuals, with altered 4-hydroxyantipyrine levels.

Keywords:
antipyrine metabolismchronic mercury intoxicationcytochrome Р4503А (CYP3А)genetic polymorphismmercury

More Related Videos

A Study of the Complexation of MercuryII with Dicysteinyl Tetrapeptides by Electrospray Ionization Mass Spectrometry
12:59

A Study of the Complexation of MercuryII with Dicysteinyl Tetrapeptides by Electrospray Ionization Mass Spectrometry

Published on: January 8, 2016

8.3K
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

13.0K

Related Experiment Videos

Last Updated: Dec 26, 2025

An Anaerobic Biosensor Assay for the Detection of Mercury and Cadmium
09:33

An Anaerobic Biosensor Assay for the Detection of Mercury and Cadmium

Published on: December 17, 2018

10.7K
A Study of the Complexation of MercuryII with Dicysteinyl Tetrapeptides by Electrospray Ionization Mass Spectrometry
12:59

A Study of the Complexation of MercuryII with Dicysteinyl Tetrapeptides by Electrospray Ionization Mass Spectrometry

Published on: January 8, 2016

8.3K
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

13.0K

Area of Science:

  • Pharmacogenomics
  • Environmental Toxicology
  • Biochemistry

Background:

  • Chronic mercury intoxication is a significant health concern, particularly for workers exposed to mercury vapors.
  • The cytochrome P450 3A (CYP3A) gene family plays a crucial role in metabolizing various xenobiotics, including potential environmental toxins.
  • Understanding the genetic predisposition to mercury toxicity is essential for developing targeted prevention and treatment strategies.

Purpose of the Study:

  • To investigate the association between polymorphic loci of CYP3A4, CYP3A5, and CYP3A7 genes and the development of chronic mercury intoxication.
  • To evaluate the relationship between specific CYP3A genotypes and mercury exposure levels, as indicated by urinary 4-hydroxyantipyrine (4-HAP) content.

Main Methods:

  • Analysis of CYP3A4 (rs2740574), CYP3A5 (rs776746), and CYP3A7 (rs2257401) gene polymorphisms in 170 men (120 mercury-exposed workers, 50 with GG-HSPA1B genotype).
  • Measurement of urinary 4-hydroxyantipyrine (4-HAP) levels in workers without intoxication (Group 1) and patients with chronic mercury intoxication (Group 2).
  • Statistical analysis to determine genotype frequencies, linkage disequilibrium, and differences in 4-HAP levels between groups.

Main Results:

  • A tendency towards increased frequency of genotypes with rare alleles in CYP3A5 and CYP3A7 was observed in the combined intoxicated group compared to the non-intoxicated group (p=0.071 and p=0.078).
  • High linkage disequilibrium was noted between rs776746 (CYP3A5) and rs2257401 (CYP3A7) (LD (r)=0.89).
  • A trend towards decreased 4-HAP levels was observed in Group 2 carriers of AA-CYP3A4 and GG-CYP3A5 genotypes compared to Group 1 (p=0.056 and p=0.065).

Conclusions:

  • The study suggests a potential, though not definitive, role for CYP3A gene polymorphisms in the susceptibility to chronic mercury intoxication.
  • Further research is needed to elucidate the precise mechanisms by which CYP3A enzymes influence mercury neurotoxicity.
  • Genetic screening of CYP3A variants might offer insights into individual risk for mercury-induced health effects.